Ideaya Biosciences, Inc. · NASDAQ:IDYA
Ideaya Biosciences — Investor Presentation (November 2019)
25 slides from Ideaya Biosciences's investor presentation, Nov 13, 2019
Slide 1: IDEAYA Biosciences Corporate Presentation November 2019
IDEAYA Biosciences Corporate Presentation November 2019 Exhibit 99.2 EXHIBIT 99. 2 IDEAYA Biosciences Corporate Presentation November 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement CONFIDENTIAL Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks
Slide 3: IDEAYA Highlights
IDEAYA HIGHLIGHTS Synthetic Lethality (SL) Direct Targeting of Oncogenic Pathways PRECISION MEDICINE TARGET CLASSES IDEAYA Biosciences Oncology Focused Precision Medicine Company Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instability Mutations in GNA11
Slide 4: IDEAYA Organization: Proven Leadership Team From Top Oncology Companies
IDEAYA Organization Proven Leadership Team From Top Oncology Companies Michael Dillon, Ph.D. SVP, Chief Scientific Officer, Head of Research Julie Hambleton, M.D. SVP, Chief Medical Officer, Head of Development Jason Throne, J.D. VP, General Counsel Bao Truong, VP, Head of Regulatory Mark Lackner, P
Slide 5: IDEAYA's Precision Medicine Oncology Pipeline
IDEAYA’s Precision Medicine Oncology Pipeline Indication Biomarker Preclinical IND Phase 1 Phase 2 Registration Enabling Status IDE196 PKC inhibitor MUM Mono GNAQ/11 Launch Single-Arm Ph2 Trial Q4’19 Potential Registration-Enabling Non-MUM Solid Tumors GNAQ/11 Ph1/2 Non-MUM Basket Trial FPI Q3’19 MU
Slide 6: GNAQ or GNA11 mutations can lead to activation of PKC signaling
Mutations in small GTPases, GNAQ or GNA11, can lead to activation of PKC signaling, a genetic driver of cancer Van Raamsdonk, CD, et. al, Nature 2009; Van Raamsdonk CD, et. al, NEJM 2010; Piperno-Neumann S, et. al, J Clin Oncol 2014; Oncotarget, May 2016, Carita et al Activating GNAQ or GNA11 mutati
Slide 7: IDE196 Opportunity – Potential Addressable Market
Rare Oncology Indication Comps IDE196 Opportunity – Potential Addressable Market Solid Tumors Having GNAQ/11 Mutations GNAQ/GNA11 Patients in US & EU5 (Patients in 1,000’s) US and EU5 ~3.5 K GNAQ/11 Metastatic Uveal Melanoma (MUM) ~2.5 K GNAQ/11 Other Solid Tumors (Hotspot) ROS1 Advanced NSCLC per T
Slide 8: IDE196 is a potent and selective PKC Inhibitor
IDE196 is a potent and selective Protein Kinase C (PKC) Inhibitor IDE196 Compound Profile • Potent across key PKC isoforms • Single agent tumor regression in GNAQ/GNA11 mutant xenograft Highly selective against other kinases IDE196 IC50 (nM) PKC Activity IDE196 IC50 (nM) PKC Activity Classical Novel
Slide 9: Metastatic Uveal Melanoma: High Unmet Medical Need
Metastatic Uveal Melanoma (MUM) Removal of the eye (”enucleation”) Surgery to save eye Radiation treatment - Iodine-125 plaque - Proton beam Other treatments - Laser, tumor resection Treatment Options for Primary Disease ~ 90% of uveal melanoma patients harbor activating GNAQ or GNA11 mutation ~ 50%
Slide 10: IDE196 Phase 1 Dose Escalation Monotherapy Results in MUM
IDE196 Phase 1 Dose Escalation monotherapy results in Metastatic Uveal Melanoma AACR 2019, Novartis Data; Data cut-off: Sep 30 2018; Response data by investigator assessment Treatment LXS196 200 mg BID LXS196 300 mg BID LXS196 400 mg BID -30 22/30 (73%) Disease Control Rate (SD+PR+CR) 8/30 (27%) Tum
Slide 11: Prior clinical trials in MUM show unmet medical need
Prior clinical trials in MUM show unmet medical need IDE196 Phase 1 monotherapy data provides potential to be backbone of care in Metastatic Uveal Melanoma Agent Trial Disease Control Rate % (SD+PR+CR) >30% Tumor Regression ORR % (CR+PR) Duration of CR/PR Responses (days) Median PFS (months) IDE196
Slide 12: GNAQ/GNA11 Mutations Found in Multiple Cancers
GNAQ/GNA11 Mutations Found in Multiple Cancers Phase 1/2 Tissue Type Agnostic Basket Trial FPI Q2 2019 GNAQ/GNA11 Mutations Found in ctDNA ctDNA Diagnostics for Patient Identification Circulating tumor DNA with GNAQ/GNA11 mutations may be an early indicator of disease progression May enable early de
Slide 13: Existing Commercially Available Diagnostics Provide Path to Execute Basket Trial
Existing Commercially Available Diagnostics Provide Path to Execute GNAQ/GNA11 Basket Trial GNAQ/GNA11 mutations listed on Foundation NGS panel GNAQ/GNA11 mutations listed on ctDNA liquid biopsy panel GNAQ/GNA11 mutations listed on ctDNA liquid biopsy panel Point Mutations (SNVs) (73 Genes) AKT1 ALK
Slide 14: GNAQ/GNA11 Mutations and TMB in Skin Melanoma
GNAQ/GNA11 Mutations and TMB in Skin Melanoma BRAF/NRAS & GNAQ/GNA11 Profile GNAQ/GNA11 Skin Melanoma patients are genetically distinct from BRAF & have low TMB, providing a lack of therapeutic options Skin Melanoma BRAF – non-V600E BRAF – V600E* NRAS- MT* GNAQ/GNA11- Q209 GNAQ/GNA11-R183 = exclusiv
Slide 15: IDE196 Development Plan: Monotherapy and Combinations
IDE196 Development Plan Monotherapy and Combinations IDE196 Monotherapy Phase 1/2 GNAQ/GNA11 Basket Trial Cutaneous Melanoma (CM) Colorectal, Other Solid Tumors IDE196 Monotherapy Phase 2 Potential Registration-Enabling Trial Metastatic Uveal Melanoma Single-arm trial design based on EOP1 meeting wi
Slide 16: PKC-delta implicated in EGFRi Resistance
PKC-delta implicated in EGFRi Resistance IDE196 Potential Indication Expansion EGFRi-resistant NSCLC Targeting PKC-delta as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer Inhibition of PKC-delta sensitizes TKI-resistant EGFR-mutant NSC
Slide 17: IDEAYA Synthetic Lethality Approach
IDEAYA Synthetic Lethality Approach Synthetic Lethality Background Synthetic Lethality (SL) Platform & Capabilities Emerging Class of Precision Medicine Targets TSG = tumor suppressor gene Generating, validating and integrating vast synthetic lethality data sets: Discovery of novel precision medicin
Slide 18: IDEAYA Synthetic Lethality Pipeline
Today IDEAYA Synthetic Lethality Pipeline IDEAYA is advancing the next generation of biomarker-enabled Synthetic Lethality programs HRD = Homologous Recombination Deficiency, MSI = Microsatellite Instability MAT2A MTAP Deletion PARG BER, BRCA Pol-Theta HRD/BRCA Dual CRISPR SL Targets PARP HRD/BRCA L
Slide 19: MAT2A Inhibition is Synthetic Lethal with MTAP Deletion
MAT2A Inhibition is Synthetic Lethal with MTAP Deletion MTAP Deletion Prevalence ~15% of all Solid Tumors MTAP Deletion Prevalence MTAP-MAT2A SL Biology Data from The Cancer Genome Atlas data in cBioPortal Cancer Type N MTAP Deletions (%) Glioblastoma 592 41 Mesothelioma 87 32 Esophageal 95 28 Bladd
Slide 20: MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-Null Cell Line
IDEAYA MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-Null Cell Line & PD Modulation of SAM Levels PD Modulation: SAM Levels in HCT116 Cell Line Synthetic Lethality in HCT116 Cell Line IDB361 IDEAYA data, including for IDB361 as illustrative compound Structurally Enabled Lead Optimization
Slide 21: MAT2A inhibitors demonstrate in vivo efficacy and PD modulation
IDEAYA MAT2A inhibitors demonstrate potent in vivo efficacy and PD modulation in HCT116 MTAP-/- xenograft model Lead series of IDEAYA MAT2A inhibitors Demonstrate ~60-100% tumor growth inhibition (TGI) at efficacious dose ranges of 3 to 30 mg/kg QD Comparable to higher TGI than Agios AGI-25696 at ≥1
Slide 22: MAT2A inhibitors efficacious in endogenous MTAP-/- models
IDEAYA data AACR-NCI-EORTC meeting, 2019; webcast: https://investor.agios.com/events/event-details/agios-live-webcast-aacr-nci-eortc IDEAYA MAT2A inhibitors efficacious in endogenous MTAP-/- models and have potential to differentiate from AG-270 Efficacious in endogenous in vivo MTAP-/- KP4 xenograf
Slide 23: Pol theta Drug Discovery
Pol theta Drug Discovery Pol theta Synthetic Lethality Program Candidate Biomarkers: BRCA/HRD Pol theta Biomarker IDEAYA Pol theta inhibitor cell potency in DLD1 BRCA2 line In vivo evaluation of lead series ongoing Pol theta synthetic lethality with BRCA1/2 in HCCT116 cells Synthetic Lethal Screen w
Slide 24: Werner Drug Discovery
Discovery: completed multiple hit discovery campaigns using a range of screening formats and compound libraries Screening: robust suite of biochemical and biophysical assays to identify WRN inhibitors and differentiate false positives Lead Series: identified a lead series with <100 nanomolar IC50 po
Slide 25: Pipeline Target Milestones through 2020
IDEAYA’s Precision Medicine Oncology Pipeline Target Milestones through 2020 Indication Biomarker Preclinical IND Phase 1 Phase 2 Registration Enabling Target Milestone through 2020 IDE196 PKC inhibitor MUM Mono GNAQ/11 Ph 1/2 Interim Data Q2/Q3 2020 Non-MUM Solid Tumors GNAQ/11 Ph 1/2 Interim Data
IDEAYA Biosciences — Investor Presentation (November 2019) on 6ix